ClinicalTrials.gg
Enrolling by invitationNCT06303531Updated Mar 25, 2024

Efficacious Iron for Iron Deficiency Anemia in Adults Aged ≥18 Years

An interventional study of Ferrous Fumarate and Polysaccharide Iron in Iron Deficiency Anemia, sponsored by Dr. Anil K. Gupta Medicine Professional Corporation. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-25.

Sponsored by Dr. Anil K. Gupta Medicine Professional Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency — 2 open to participants now, 2 under way, none of them phase 3. ferrous fumarate · Anemia, Iron-Deficiency.

Planned enrollment
4th of 12
111 · median 74
Started
2024
the only one that year
No phase
6 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Dr. Anil K. Gupta Medicine Professional Corporation

Among the 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency, this one is the 4th largest by planned enrollment, is the only one that started in 2024, is one of 6 with no phase, and was the 11th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

2 of the 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ferrous fumarate

ferrous fumarate: first FDA approval 1978 (NORMINEST FE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

Iron deficiency anemia (IDA) is a widespread condition affecting many people globally. Despite the many cases of IDA, there are few studies that compare the effectiveness of different types of iron supplements with a greater emphasis on the cost of supplements and their tolerability. This study aims to conduct a comparison between different iron supplements to determine the superiority of the iron supplements Ferrous Ascorbate (EBMfer) and Ferrous Fumarate (Eurofer) over polysaccharide iron (FeraMax). This comparison will be conducted by determining the change in hemoglobin levels for participants in this trial over a 3-month period.

03

Conditions studied

  • Iron Deficiency Anemia

Keywords

  • Anemia
  • Iron Deficiency
  • Ferrous Fumarate
  • Polysaccharide Iron
  • Ferrous Ascorbate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be ≥18 years of age when signing the .
  2. Participants with iron deficiency anemia are defined as follows for the purpose of this study:

Male: > 80 to ≤135g/L and Serum Ferritin \< 30 ug/L Female: Hgb > 80 to ≤120g/L and Serum Ferritin \< 30 ug/L 2b. Local lab done prior to 7 days can be enrolled in the trial provided all the inclusion and exclusion criteria are met.

2c. Previously Screen Failed subjects not meeting the \<15 ug/L ferritin criteria can be rescreened once ICF is signed.

2d. Subjects not on iron supplement and meeting all the randomization criteria do not have to wait for 7 days for visit 2.

  1. Sex and /Barrier Requirements, Male and Female participants: None 4. Must have given written informed consent (signed and dated) 5. Medication Stopping: If the participant is currently on an iron supplement, they must be willing to discontinue the medication upon signing the Informed Consent Form (ICF) and throughout the study. 6. Protocol Compliance: Participants must be able to comply with the requirements outlined in the study protocol

Exclusion criteria

Exclusion Criteria:

  1. (Hb) ≤ 80 g/L
  2. Medical history of current hematological disorders other than iron deficiency anemia (e.g., aplastic anemia, megaloblastic anemia, sideroblastic anemia, pernicious anemia, thalassemia trait, thalassemia, sickle cell anemia, etc.).
  3. Medical history of chronic renal disease, current history of any known inflammatory disorder, and any chronic medical condition that, in the opinion of the Principal Investigator, would compromise participant safety.
  4. Medical history or evidence of intestinal malabsorption, malabsorption syndrome, hemochromatosis, and hemosiderosis, hypochlorhydria, achlorhydria, gastrectomy, and gastrojejunostomy.
  5. History of occult blood in the stool.
  6. Obvious internal or external bleeding as documented by medical history if considered in the investigator's opinion.
  7. Severe and uncontrolled diseases, including serious psychological disorders, that are likely to interfere with the study.
  8. Significant co-morbidity, such as a severe chronic medical condition unrelated to iron deficiency that is apparent on history or laboratory tests.
  9. Iron Supplementation: Throughout the study duration, participants are not allowed to receive other sources of iron supplementation, including but not limited to other oral iron tablets and intravenous iron therapy.
  10. Prohibited Medication: Inability to withhold prohibited medications. Prohibited medications include Proton Pump Inhibitors, Cholestyramine, colestipol, and new anticoagulant therapy initiated in the past six months (e.g., warfarin, apixaban, dabigatran, edoxaban, rivaroxaban).
  11. Multivitamin and Mineral Supplements: Not willing to discontinue multivitamin and mineral supplements containing 35 mg or more of elemental iron per day on the day of screening and throughout the study.
  12. Blood Transfusion, Blood Donation, and IV Iron Therapy: History of blood transfusion, blood donation, or significant blood loss (e.g., due to an accident or surgery), or intravenous iron therapy in the past four months.
  13. Participants must not be currently participating in any other interventional clinical trial.
  14. Pregnancy: A urine dipstick pregnancy test will be performed at Visit 1, and pregnant individuals will be excluded from the study.
  15. Desire to Conceive Within the Next 13 weeks: This criterion includes patients who are actively trying to conceive or are receiving treatment to facilitate conception. They will be excluded from the study.
  16. Known or Suspected to Iron: Individuals with a known or suspected hypersensitivity to iron or any of the components of Ferrous Fumarate (Eurofer), Polysaccharide Iron (FeraMAX), and Ferrous Ascorbate (EBMfer) will be excluded.
  17. Planned Surgery: Participants with planned surgery during the study or those who had surgery within two weeks before the screening visit will be excluded.
  18. Difficulties with Blood Sampling: Individuals with difficulties related to blood sampling that might hinder the study procedures will be excluded.
  19. Alcohol or Drug Abuse: Participants showing evidence of alcohol or drug abuse that, in the opinion of the investigator, could interfere with study compliance or prevent understanding of the study's objectives and procedures will be excluded.
  20. Inability to Follow Study Procedures: This includes individuals who are unable to follow study procedures due to factors like language problems or self-reported psychological disorders.
  21. Enrollment of the Investigator, Family Members, and Clinic Employees: The investigator, their family members, and clinic employees will not be eligible to participate in the study to avoid any potential conflicts of interest
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (estimated)

Study arms

  • Active comparator
    Eurofer

    Ferrous Fumarate - 300 mg

    Dietary Supplement: Ferrous Fumarate

  • Active comparator
    FeraMAX

    Polysaccharide Iron - 150mg

    Dietary Supplement: Polysaccharide Iron

  • Active comparator
    EBMfer

    Ferrous Ascorbate - 100 mg

    Dietary Supplement: Ferrous Ascorbate

Interventions

  • Dietary supplementFerrous Fumarate

    Ferrous Fumarate - 300 mg

    Also known as: Eurofer

  • Dietary supplementPolysaccharide Iron

    Polysaccharide Iron - 150 mg

    Also known as: FeraMAX

  • Dietary supplementAscorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ferrous Ascorbate - 100 mg

    Also known as: EBMfer

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin Levels

    Hemoglobin levels measured using a hematology panel at baseline and 12 weeks

    Time frame: 12 Weeks from Baseline

Secondary outcomes

  1. Change in Serum Ferritin

    Serum ferritin measured using a hematology panel at baseline and 12 weeks

    Time frame: 12 Weeks from Baseline

  2. Tolerability of Study Medication - Discontinuation Rate

    Discontinuation rates measured using subject compliance over the trial period of 12 weeks. Discontinuation rate will be measured based on subject compliance with study medication as a rate based on time.

    Time frame: 12 Weeks from Baseline

07

Study locations

1 site
08

References and documents

Publications

  • Ganguly S. Comparison between Ferrous Ascorbate and Colloidal Iron in the Treatment of Iron Deficiency Anemia in Children from Kolkata, India. BJMMR 2012; 2: 195-205.
  • Powers JM, Buchanan GR, Adix L, Zhang S, Gao A, McCavit TL. Effect of Low-Dose Ferrous Sulfate vs Iron Polysaccharide Complex on Hemoglobin Concentration in Young Children With Nutritional Iron-Deficiency Anemia: A Randomized Clinical Trial. JAMA. 2017 Jun 13;317(22):2297-2304. doi: 10.1001/jama.2017.6846. PubMed 28609534 ↗
  • Liu TC, Lin SF, Chang CS, Yang WC, Chen TP. Comparison of a combination ferrous fumarate product and a polysaccharide iron complex as oral treatments of iron deficiency anemia: a Taiwanese study. Int J Hematol. 2004 Dec;80(5):416-20. doi: 10.1532/ijh97.a10409. PubMed 15646652 ↗
  • Moe S, Grill AK, Allan GM. Newer iron supplements for anemia. Can Fam Physician. 2019 Aug;65(8):556. No abstract available. PubMed 31413026 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2025, 12 months after the start.

Of 133 non-industry interventional studies with no phase under Anemia, Iron-Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 12 months is close to that.

Counting every sponsor, half of 142 studies reached it within 11 months; a quarter within 3 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Mar 12, 2024
StartActual
Feb 24, 2024
Primary completionEst.
Feb 2025
CompletionEst.
Feb 2025
Last update
Mar 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06303531
Lead sponsor
Dr. Anil K. Gupta Medicine Professional Corporation
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Feb 24, 2024
Primary completion
Feb 2025 (estimated)
Completion
Feb 2025 (estimated)
Last update
Mar 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ferrous fumarate · Ascorbic Acid

Start the discussion